29.49
+0.41(+1.41%)
Currency In USD
| Previous Close | 29.08 |
| Open | 28.98 |
| Day High | 29.65 |
| Day Low | 28.84 |
| 52-Week High | 33.6 |
| 52-Week Low | 2.01 |
| Volume | 17,873 |
| Average Volume | 2.68M |
| Market Cap | 39.14M |
| PE | -2.44 |
| EPS | -12.11 |
| Moving Average 50 Days | 17.8 |
| Moving Average 200 Days | 7.19 |
| Change | 0.41 |
If you invested $1000 in Galecto, Inc. (GLTO) since IPO date, it would be worth $78.64 as of December 25, 2025 at a share price of $29.49. Whereas If you bought $1000 worth of Galecto, Inc. (GLTO) shares 3 years ago, it would be worth $1,112.83 as of December 25, 2025 at a share price of $29.49.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Galecto, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Dec 16, 2025 10:00 PM GMT
BOSTON, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Galecto, Inc. (the “Company” or “Galecto”) (Nasdaq: GLTO) today announced that the Company’s Board of Directors approved the grant of non-qualified stock options to purchase 312,535 shares of the Company’s
Galecto Announces Acquisition of Damora Therapeutics
GlobeNewswire Inc.
Nov 10, 2025 12:00 PM GMT
Acquisition of Damora and concurrent oversubscribed $285 million private investment positions the company to advance potentially best-in-class portfolio to improve outcomes in patients with Myeloproliferative Neoplasms Damora Therapeutics, the sixth
Galecto Reports Third Quarter 2025 Operating and Financial Results
GlobeNewswire Inc.
Nov 06, 2025 9:30 PM GMT
BOSTON, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for oncology and liver diseases, today announced its operating and financial results for t